103 related articles for article (PubMed ID: 12781776)
1. Identification of epitopes on cytochrome P450 3A4/5 recognized by monoclonal antibodies.
Parimoo B; Mishin VM; Busch CM; Thomas PE
Arch Biochem Biophys; 2003 Jun; 414(2):244-54. PubMed ID: 12781776
[TBL] [Abstract][Full Text] [Related]
2. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
[TBL] [Abstract][Full Text] [Related]
3. Epitope mapping of rat cytochrome P450 2B1 using glutathione S-transferase-2B1 fusion constructs.
Parimoo B; Thomas PE
Arch Biochem Biophys; 2000 Aug; 380(1):117-25. PubMed ID: 10900140
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.
Allqvist A; Miura J; Bertilsson L; Mirghani RA
Eur J Clin Pharmacol; 2007 Feb; 63(2):173-9. PubMed ID: 17200836
[TBL] [Abstract][Full Text] [Related]
5. Territrems B and C metabolism in human liver microsomes: major role of CYP3A4 and CYP3A5.
Peng FC; Chang CC; Yang CY; Edwards RJ; Doehmer J
Toxicology; 2006 Feb; 218(2-3):172-85. PubMed ID: 16337070
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory anti-CYP3A4 peptide antibody: mapping of inhibitory epitope and specificity toward other CYP3A isoforms.
Wang RW; Newton DJ; Liu NY; Shou M; Rushmore T; Lu AY
Drug Metab Dispos; 1999 Feb; 27(2):167-72. PubMed ID: 9929498
[TBL] [Abstract][Full Text] [Related]
8. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
[TBL] [Abstract][Full Text] [Related]
9. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450.
Domanski TL; Finta C; Halpert JR; Zaphiropoulos PG
Mol Pharmacol; 2001 Feb; 59(2):386-92. PubMed ID: 11160876
[TBL] [Abstract][Full Text] [Related]
10. [Identification of a novel antigenic epitope on GST fusion-expressed and ORF2-encoded proteins of hepatitis E virus].
Liang JH; Liang LM; Dong M; Han ZG; Dong C; Meng JH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):321-3, 327. PubMed ID: 18394332
[TBL] [Abstract][Full Text] [Related]
11. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
[TBL] [Abstract][Full Text] [Related]
12. Inhibition kinetics of monoclonal antibodies against cytochromes P450.
Mei Q; Tang C; Lin Y; Rushmore TH; Shou M
Drug Metab Dispos; 2002 Jun; 30(6):701-8. PubMed ID: 12019198
[TBL] [Abstract][Full Text] [Related]
13. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes.
Nielsen TL; Rasmussen BB; Flinois JP; Beaune P; Brosen K
J Pharmacol Exp Ther; 1999 Apr; 289(1):31-7. PubMed ID: 10086984
[TBL] [Abstract][Full Text] [Related]
14. Role of cytochrome P450 IA2 in acetanilide 4-hydroxylation as determined with cDNA expression and monoclonal antibodies.
Liu G; Gelboin HV; Myers MJ
Arch Biochem Biophys; 1991 Feb; 284(2):400-6. PubMed ID: 1989524
[TBL] [Abstract][Full Text] [Related]
15. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
Wang YH; Jones DR; Hall SD
Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4.
Gelboin HV; Krausz KW; Goldfarb I; Buters JT; Yang SK; Gonzalez FJ; Korzekwa KR; Shou M
Biochem Pharmacol; 1995 Nov; 50(11):1841-50. PubMed ID: 8615863
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory anti-peptide antibody against human CYP3A4.
Wang RW; Lu AY
Drug Metab Dispos; 1997 Jun; 25(6):762-7. PubMed ID: 9193880
[TBL] [Abstract][Full Text] [Related]
18. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
[TBL] [Abstract][Full Text] [Related]
19. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory and noninhibitory monoclonal antibodies to human cytochrome P450 2E1.
Gelboin HV; Goldfarb I; Krausz KW; Grogan J; Korzekwa KR; Gonzalez FJ; Shou M
Chem Res Toxicol; 1996 Sep; 9(6):1023-30. PubMed ID: 8870991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
